This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence in a Treatment that’s setting the standard3-5
The efficacy and safety of IBRANCE® has been evaluated in two large Randomised Control Trials (RCTs) in women with HR+/HER2- metastatic Breast Cancer (mBC) as part of Pfizer’s robust PALOMA Clinical Trial Programme in Breast Cancer.1-5
IBRANCE® + Aromatase Inhibitor (AI) PALOMA-2 Clinical Trial results including efficacy and safety outcomes.
IBRANCE® + Fulvestrant (FUL) PALOMA-3 Clinical Trial results including efficacy and safety outcomes.
Real World Evidence (RWE) for IBRANCE® (pabociclib) in advanced breast cancer
IBRANCE® safety information and frequent adverse events
AI : Aromatase Inhibitor, ER+ / HER2− : Oestrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative, ET : Endocrine Therapy, HR+ / HER2- : Hormone Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative, LHRH : Luteinising Hormone-Releasing Hormone, mBC : metastatic Breast Cancer, RCT: Randomised Controlled Trial, SmPC: Summary of Product Characteristics.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021